TherapeuticsMD (TXMD) vs. Its Peers Head to Head Survey
by Scott Moore · The Cerbat GemTherapeuticsMD (NASDAQ:TXMD – Get Free Report) is one of 897 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare TherapeuticsMD to related businesses based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, valuation, risk and earnings.
Profitability
This table compares TherapeuticsMD and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TherapeuticsMD | -6.64% | -1.09% | -0.78% |
| TherapeuticsMD Competitors | -2,380.91% | -221.72% | -15.99% |
Analyst Recommendations
This is a breakdown of current ratings and price targets for TherapeuticsMD and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TherapeuticsMD | 1 | 0 | 0 | 0 | 1.00 |
| TherapeuticsMD Competitors | 7765 | 13847 | 25696 | 1031 | 2.41 |
As a group, “Pharmaceuticals” companies have a potential upside of 23.99%. Given TherapeuticsMD’s peers stronger consensus rating and higher possible upside, analysts plainly believe TherapeuticsMD has less favorable growth aspects than its peers.
Insider & Institutional Ownership
30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 32.4% of shares of all “Pharmaceuticals” companies are held by institutional investors. 1.7% of TherapeuticsMD shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
TherapeuticsMD has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, TherapeuticsMD’s peers have a beta of -4.30, suggesting that their average share price is 530% less volatile than the S&P 500.
Earnings and Valuation
This table compares TherapeuticsMD and its peers revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| TherapeuticsMD | $3.02 million | -$570,000.00 | 90.00 |
| TherapeuticsMD Competitors | $3.54 billion | $3.17 billion | 546.63 |
TherapeuticsMD’s peers have higher revenue and earnings than TherapeuticsMD. TherapeuticsMD is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Summary
TherapeuticsMD peers beat TherapeuticsMD on 9 of the 13 factors compared.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.